You just read:

IPI-549 Alters the Immune-Suppressive Microenvironment and Enhances the Activity of Checkpoint Inhibitors in Preclinical Models

News provided by

Infinity Pharmaceuticals, Inc.

Apr 18, 2016, 08:00 ET